↓ Skip to main content

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Overview of attention for article published in Journal of Clinical Oncology, June 2019
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Readers on

mendeley
387 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 89 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 387 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 387 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Other 44 11%
Researcher 40 10%
Student > Master 29 7%
Student > Ph. D. Student 21 5%
Student > Bachelor 20 5%
Other 58 15%
Unknown 175 45%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 111 29%
Biochemistry, Genetics and Molecular Biology 33 9%
Agricultural and Biological Sciences 12 3%
Pharmacology, Toxicology and Pharmaceutical Science 9 2%
Nursing and Health Professions 8 2%
Other 26 7%
Unknown 188 49%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 132. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2026.
All research outputs
#402,431
of 34,826,706 outputs
Outputs from Journal of Clinical Oncology
#775
of 32,900 outputs
Outputs of similar age
#6,621
of 399,893 outputs
Outputs of similar age from Journal of Clinical Oncology
#18
of 747 outputs
Altmetric has tracked 34,826,706 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,900 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.6. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 399,893 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 747 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.